|
Group
|
Discovery cohort
|
Validation cohort
|
|---|
|
Chemoresistant OS (n=6)
|
Control (n=6)
|
Chemoresistant OS (n=35)
|
Control (n=35)
|
|---|
|
Age (years)
|
|
Mean±SD
|
9.6±4.2
|
9.6±4.2
|
9.9±4.9
|
10.1±5.2
|
|
Range
|
7–14
|
7–14
|
6–16
|
6–16
|
|
Gender n (%)
|
|
Male
|
3 (50)
|
3 (50)
|
21 (60)
|
23 (66)
|
|
Female
|
3 (50)
|
3 (50)
|
14 (40)
|
12 (34)
|
|
Tumor stage n (%)
|
|
Stage IIA
|
2 (33)
|
2 (33)
|
8 (23)
|
7 (20)
|
|
Stage IIB
|
2 (33)
|
2 (33)
|
13 (37)
|
13 (37)
|
|
Stage III
|
2 (33)
|
2 (33)
|
14 (40)
|
15 (43)
|
|
Body mass index (kg/m2)
|
17.5±4.0
|
18.2±4.1
|
17.7±3.8
|
18.3±4.0
|
|
Tumor necrosis (%)
|
94.1±2.8
|
70.8±9.2*
|
93.5±3.6
|
73.6±12.2*
|
- Note: OS osteosarcoma. *p < 0.05 vs Chemoresistant OS.
